These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15969246)

  • 21. Intramuscular neridronate in postmenopausal women with low bone mineral density.
    Adami S; Gatti D; Bertoldo F; Sartori L; Di Munno O; Filipponi P; Marcocci C; Frediani B; Palummeri E; Fiore CE; Costi D; Rossini M
    Calcif Tissue Int; 2008 Nov; 83(5):301-7. PubMed ID: 18946626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
    Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
    Gertz BJ; Shao P; Hanson DA; Quan H; Harris ST; Genant HK; Chesnut CH; Eyre DR
    J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
    Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
    Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis.
    Eviö S; Tarkkila L; Sorsa T; Furuholm J; Välimäki MJ; Ylikorkala O; Tiitinen A; Meurman JH
    Oral Dis; 2006 Mar; 12(2):187-93. PubMed ID: 16476042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reduction of the Nordin index after therapy with oral alendronate in patients with postmenopausal osteoporosis].
    Busi S; Catalano A
    Clin Ter; 1995 Dec; 146(12):857-9. PubMed ID: 8681505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose reduction and discontinuation of alendronate in postmenopausal osteoporotic women who were receiving estrogen therapy.
    Palomba S; Orio F; Russo T; Colao A; Lombardi G; Zullo F
    Fertil Steril; 2004 Feb; 81(2):476-8. PubMed ID: 14967398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Age-related and menopause-related changes of urinary excretion of C- and N-terminal cross-linked telopeptides of type I collagen and the relationships thereof with menopause-related bone loss].
    Liu SP; Liao EY; Wu XP; Cao XZ; Shan PF; Su X
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):371-5. PubMed ID: 16677543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
    Uretmen S; Gol M; Cimrin D; Irmak E
    Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis.
    Yasui T; Itoh Y; Okada A; Hamamoto S; Hirose M; Kobayashi T; Tozawa K; Kohri K
    Urol Int; 2009; 83(2):226-9. PubMed ID: 19752622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alendronate: a new bisphosphonate for the treatment of osteoporosis.
    Keen RW; Spector TD
    Br J Clin Pract; 1996 Jun; 50(4):211-7. PubMed ID: 8759568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of supplemental calcium on serum and urinary calcium in osteoporotic patients.
    Licata AA; Jones-Gall D
    J Am Coll Nutr; 1992 Apr; 11(2):164-7. PubMed ID: 1578092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Alendronate (Fosamax 10 mg). The first amino-biphosphate for the treatment of women with postmenopausal osteoporosis].
    Geburtshilfe Frauenheilkd; 1996 Oct; 56(10 Suppl):1-4. PubMed ID: 9022376
    [No Abstract]   [Full Text] [Related]  

  • 35. Spine studies to remain part of bone analysis.
    Diagn Imaging (San Franc); 1998 Nov; Suppl Bone Mass():6. PubMed ID: 10345144
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of three different calcium preparations on urinary calcium and hydroxyproline excretion in postmenopausal osteoporotic women.
    Need AG; Horowitz M; Morris HA; Nordin BE
    Eur J Clin Nutr; 1991 Jul; 45(7):357-61. PubMed ID: 1935862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate addition to stable hormone replacement therapy increases bone mineral density in postmenopausal women.
    Boulos P; Sebaldt RJ; Goldsmith CH
    J Rheumatol; 2002 May; 29(5):1110-1. PubMed ID: 12022339
    [No Abstract]   [Full Text] [Related]  

  • 38. [Osteoporosis medications. Bisphosphonates exceed the others].
    MMW Fortschr Med; 2003 Oct; 145(42):66. PubMed ID: 14655453
    [No Abstract]   [Full Text] [Related]  

  • 39. Alendronate treatment for osteoporosis.
    Brager R
    Adv Nurse Pract; 1997 Mar; 5(3):28-34. PubMed ID: 9459879
    [No Abstract]   [Full Text] [Related]  

  • 40. The effects of alendronate in postmenopausal women with osteoporosis.
    Yaniv I
    Osteoporos Int; 2003 Jan; 14(1):90-1. PubMed ID: 12577190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.